Drug Trial Radar · NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Aug 26, 2025
Primary completion
Apr 30, 2028
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Relay Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Conditions
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Hormone Receptor Positive Tumor
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
Interventions
ZovegalisibDrug
400 mg orally BID administered daily on a 28-day treatment cycle
CapivasertibDrug
400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
FulvestrantDrug
500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR)Time frame: The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months
Locations
254 sites in 27 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Stanford Women's Cancer Center
Palo Alto, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
University of California San Diego Moores Cancer Center
San Diego, California · Recruiting
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Kaiser Permanente Medical Center
Vallejo, California · Recruiting
Rocky Mountain Cancer Centers, LLP
Longmont, Colorado · Recruiting
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut · Recruiting
Medical Oncology Hematology Consultants, P.A.
Newark, Delaware · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
AdventHealth
Altamonte Springs, Florida · Recruiting
Florida Cancer Specialists-South
Fort Myers, Florida · Recruiting
Cancer Care Centers of Brevard, Inc
Palm Bay, Florida · Recruiting
Atlanta Cancer Care - Northside Hospital
Atlanta, Georgia · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Recruiting
Community Health Network, Inc
Indianapolis, Indiana · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Cancer Center of Kansas
Wichita, Kansas · Recruiting
Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins
Baltimore, Maryland · Recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Profound Research LLC
Royal Oak, Michigan · Recruiting
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota · Recruiting
University of Mississippi Medical Center
Jackson, Mississippi · Recruiting
Washington University School of Medicine- Siteman Cancer Center
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Renown Health Medical Oncology
Reno, Nevada · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Oregon Health & Science University, Knight Cancer Institute
Portland, Oregon · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
Showing 40 of 254 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.